About Dexcom
Dexcom is a company based in San Diego (United States) founded in 1999. Dexcom has raised $52.5 million across 8 funding rounds from investors including HHS, Warburg Pincus and Canaan. The company has 10,300 employees as of December 31, 2024. Dexcom has completed 2 acquisitions, including SweetSpot Diabetes and TypeZero Technologies. Dexcom offers products and services including Dexcom G7 and Dexcom App. Dexcom operates in a competitive market with competitors including Livongo, Senseonics, One Drop, mySugr and Jana Care, among others.
- Headquarter San Diego, United States
- Employees 10300 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dexcom, Inc.
-
Annual Revenue
$4.03 B (USD)11.34as on Dec 31, 2024
-
Net Profit
$576.2 M (USD)6.41as on Dec 31, 2024
-
EBITDA
$817.7 M (USD)4.34as on Dec 31, 2024
-
Total Equity Funding
$52.5 M (USD)
in 8 rounds
-
Latest Funding Round
$1.05 B (USD), Post-IPO
Apr 11, 2020
-
Investors
HHS
& 4 more
-
Employee Count
10300
as on Dec 31, 2024
-
Investments & Acquisitions
SweetSpot Diabetes
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Dexcom
Dexcom is a publicly listed company on the NASDAQ with ticker symbol DXCM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Dexcom
Dexcom offers a comprehensive portfolio of products and services, including Dexcom G7 and Dexcom App.
Real-time glucose monitoring device that reduces fingerstick needs.
App for viewing glucose data on smartphones and smartwatches.
People of Dexcom
Unlock access to complete
Unlock access to complete
Software Development Team
241 people
Leadership Team
61 people
Product Management Team
60 people
Senior Team
46 people
Sales and Marketing
42 people
Human Resources and Administration
31 people
Staff Team
28 people
Finance and Accounting
25 people
Unlock access to complete
Funding Insights of Dexcom
Dexcom has successfully raised a total of $52.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.05 billion completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dexcom
Dexcom has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Warburg Pincus and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage private equity investments are pursued across diverse sectors.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in US life-sciences and tech companies.
|
Locked | Locked | Locked |
Investor details for Dexcom
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dexcom
Dexcom has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include SweetSpot Diabetes and TypeZero Technologies.
Investment portfolio details for Dexcom
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Device for continuous glucose monitoring with manually operated insulin delivery
|
Locked | Locked | 2013 | Locked | |
|
Platform to aggregate and analyze blood glucose data from devices
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Dexcom
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Dexcom
Detailed financials for Dexcom
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dexcom Comparisons
Peer comparison for Dexcom
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dexcom
Dexcom operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Livongo, Senseonics, One Drop, mySugr and Jana Care, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of smart devices for diabetes management for patients and doctors
|
|
| Locked | Locked | Locked |
Implantable continuous glucose monitoring systems are provided for diabetes management.
|
|
| Locked | Locked | Locked |
Provider of workforce healthcare solutions
|
|
| Locked | Locked | Locked |
Gamified apps for diabetes management and therapy are provided.
|
|
| Locked | Locked | Locked |
Mobile-based diagnostics for diabetes prevention and management are provided.
|
Detailed competitors of Dexcom
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dexcom
Complete news archive for Dexcom
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dexcom
Dexcom was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Dexcom is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Sayer is the current CEO of Dexcom.
Dexcom is a funded company, having raised a total of $52.5M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Dexcom is 10,300.
Annual revenue of Dexcom is $4.03B as on Dec 31, 2024.
Dexcom was founded in 1999 in San Diego, United States, and operates in the medical device sector focused on diabetes management. A wearable patch is offered that measures glucose levels continuously, with data transmitted wirelessly to a receiver or display device for real-time viewing. In 2022, revenues reached 3.02 billion, while net profit was recorded at 0.29 billion. The companys products support ongoing monitoring without frequent finger pricks.
Dexcom's top competitors include Senseonics, One Drop and Livongo.
Dexcom offers Dexcom G7 and Dexcom App.
Yes, Dexcom is publicly traded on NASDAQ under the ticker symbol DXCM.
Dexcom has made 2 acquisitions, including SweetSpot Diabetes, and TypeZero Technologies.
Dexcom has 5 investors. Key investors include HHS, Warburg Pincus, Canaan, Invesco Mutual Fund, and RWI Ventures.
The ticker symbol of Dexcom is DXCM on NASDAQ.